Tome Bioscience

Tome Bioscience is a Cambridge, MA-based biotechnology company pioneering programmable genomic integration (PGI) technology that enables the precise, large-scale insertion of genetic payloads into defined genomic sites without introducing double-strand DNA breaks. Founded in 2023 by genomic engineering researchers, Tome's platform addresses a key limitation of existing gene editing approaches by supporting site-specific integration of entire therapeutic genes and regulatory elements, with applications in ex vivo and in vivo cell and gene therapies. The company has raised $213M to advance its PGI technology toward clinical applications across a range of genetic and immune diseases.